Chronic Kidney Disease in the Management of people with Type 2 Diabetes in General Practice
|Dr Jo-Anne Manski-Nankervisfirstname.lastname@example.org||+61 3 9035 8019||Personal web page|
Rationale for research
General practice plays a key role in the prevention and management of chronic kidney disease (CKD), a common complication of type 2 diabetes. Previous studies have shown that screening (using blood and urine tests) and recording (in the patients medical record) of CKD in general practice is sub-optimal. This may have significant implications for safe prescribing of medications, because when kidney function is impaired, different medications or different doses of medicines may need to be used in order to prevent deterioration of kidney function and to avoid adverse medication events.
- To explore the current screening, prevalence, recording and management of CKD among people with type 2 diabetes;
- Explore whether prescribing patterns of medicines that reduce blood glucose levels (antihyperglycaemic medications) and cardiovascular medications in general practice are appropriate and safe for people with T2D who have CKD.
Australian general practice
102,000 people with type 2 diabetes attending general practices participating in the NPS Medicine Insight program
When final results will be reported/timeline/are preliminary results available:
Final reporting will be available 2017
- Dr Jo-Anne Manski-Nankervis, Diabetes Research Fellow
- Dr Phyllis Lau, Senior Research Fellow
- Associate Professor John Furler, Associate Professor and Principal Research Fellow
- Irene Blackberry,Director, John Richards Initiative | Australian Institute for Primary Care & Ageing, College of Science, Health and
- Engineering, La Trobe University, Honorary Senior Research Fellow, Department of General Practice
- Associate Professor Simon Bell, Centre for Medicine Use and Safety, Monash University
Faculty Research Themes
School Research Themes
For further information about this research, please contact the research group leader.